KAIROS PHARMA LTD (KAPA) Stock Overview
USA - NYSEARCA:KAPA - US48301N1046 - Common Stock
KAPA Key Statistics, Chart & Performance
The current stock price of KAPA is 1.16 USD. In the past month the price decreased by -4.92%. In the past year, price decreased by -21.63%.
KAPA Latest News, Press Relases and Analysis
KAPA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.68 | 405.55B | ||
| AMGN | AMGEN INC | 13.7 | 160.87B | ||
| GILD | GILEAD SCIENCES INC | 15.87 | 152.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.61 | 106.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.67 | 61.27B | ||
| ARGX | ARGENX SE - ADR | 91.01 | 51.63B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.76B | ||
| INSM | INSMED INC | N/A | 35.04B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
| NTRA | NATERA INC | N/A | 24.94B | ||
| BIIB | BIOGEN INC | 8.93 | 20.97B |
Related stock screener links
About KAPA
Company Profile
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. The company is headquartered in Los Angeles, California and currently employs 1 full-time employees. The company went IPO on 2024-09-16. The company is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
Company Info
KAIROS PHARMA LTD
2355 Westwood Blvd. #139
Los Angeles CALIFORNIA US
Employees: 1
Phone: 18184045541
KAIROS PHARMA LTD / KAPA FAQ
What is the stock price of KAIROS PHARMA LTD today?
The current stock price of KAPA is 1.16 USD. The price decreased by -0.85% in the last trading session.
What is the ticker symbol for KAIROS PHARMA LTD stock?
The exchange symbol of KAIROS PHARMA LTD is KAPA and it is listed on the NYSE Arca exchange.
On which exchange is KAPA stock listed?
KAPA stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for KAIROS PHARMA LTD stock?
9 analysts have analysed KAPA and the average price target is 8.5 USD. This implies a price increase of 632.76% is expected in the next year compared to the current price of 1.16. Check the KAIROS PHARMA LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KAIROS PHARMA LTD worth?
KAIROS PHARMA LTD (KAPA) has a market capitalization of 24.06M USD. This makes KAPA a Nano Cap stock.
How many employees does KAIROS PHARMA LTD have?
KAIROS PHARMA LTD (KAPA) currently has 1 employees.
What are the support and resistance levels for KAIROS PHARMA LTD (KAPA) stock?
KAIROS PHARMA LTD (KAPA) has a support level at 1.1 and a resistance level at 1.31. Check the full technical report for a detailed analysis of KAPA support and resistance levels.
Should I buy KAIROS PHARMA LTD (KAPA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KAPA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KAPA, evaluating the profitability, health, valuation and growth aspects
- KAIROS PHARMA LTD (KAPA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KAIROS PHARMA LTD (KAPA) Sales and EPS estimates to see what analysts future expectations are.
- KAIROS PHARMA LTD (KAPA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KAIROS PHARMA LTD (KAPA) Insider and Institutional Ownership to learn about the owners and their transactions.
- KAIROS PHARMA LTD (KAPA) Stock Chart to make your own analysis
- KAIROS PHARMA LTD (KAPA) Latest news and press-releases to stay up to date.
Does KAIROS PHARMA LTD (KAPA) stock pay dividends?
KAPA does not pay a dividend.
What is the Price/Earnings (PE) ratio of KAIROS PHARMA LTD (KAPA)?
KAIROS PHARMA LTD (KAPA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.34).
What is the Short Interest ratio of KAIROS PHARMA LTD (KAPA) stock?
The outstanding short interest for KAIROS PHARMA LTD (KAPA) is 2.83% of its float. Check the ownership tab for more information on the KAPA short interest.
KAPA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to KAPA. When comparing the yearly performance of all stocks, KAPA is a bad performer in the overall market: 75.71% of all stocks are doing better.
KAPA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KAPA. KAPA has a great financial health rating, but its profitability evaluates not so good.
KAPA Financial Highlights
Over the last trailing twelve months KAPA reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS decreased by -62.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.6% | ||
| ROE | -78.56% | ||
| Debt/Equity | 0 |
KAPA Forecast & Estimates
9 analysts have analysed KAPA and the average price target is 8.5 USD. This implies a price increase of 632.76% is expected in the next year compared to the current price of 1.16.